Genes that conferred Group A Streptococcus resistance by bombarding the bacteria with two antimicrobials: zinc ions and human group IIA secreted phospholipase A2 have been discovered by scientists.
Most people think of "strep throat" as a relatively benign infection cured by a round of antibiotics and a few days of rest.
Strep Throat
Strep Throat is a bacterial infection caused by Group A beta hemolytic streptococci. It affects most commonly infants and elderly people but adults and older children can also be affected.
Advertisement
‘The bacterium that causes strep throat -- Group A Streptococcus -- is also responsible for a number of much more dangerous disorders, including rheumatic heart disease and toxic shock syndrome. ’
Tweet it Now
With the specter of increased resistance to antibiotics, the scientific community is feeling pressure to find new ways to treat bacteria like Group A Streptococcus. And it appears that an international group of scientists has gained some insight into this microbial enemy -- and hope of a vaccine.
Group A Streptococcus has a thick cell wall that protects it from environmental hazards, including attacks from our own immune system. This bacterium is remarkably resistant to the human antimicrobial protection mechanisms for reasons that are not well understood.
![Rheumatic Heart Disease (RHD)]( "Rheumatic Heart Disease (RHD)")
Rheumatic heart disease is a sequelae of rheumatic fever that affects heart valves. Rheumatic fever occurs after an episode of strep throat or sore throat due to group A beta hemolytic streptococci.
The group of investigators -- led by Natalia Korotkova of the University of Kentucky and Nina Van Sorge of Utrecht University -- wondered: was there any "weak point" in the bacterial cell wall that could be exploited?
They found that both assays identified the same culprit: the gacH gene.
The team of more than a dozen scientists from five countries, each with a discrete expertise, further deciphered the function of this gene using a variety of biochemical, analytical and structural methods, determining that it enables Group A Streptococcus to reinforce its resistance to attack by our defense systems by modifying cell wall glycopolymers with glycerol phosphate.
"This previously unrecognized Streptococcus cell wall modification impacts host-pathogen interactions and might therefore be a very attractive target for vaccine design, especially since the gacH gene is widely distributed in the genomes of Group A Streptococcus and related bacteria," Korotkova said.
State-of-the-art NMR methods and mass-spectrometry analyses enabled the identification of this modification.
"This glycerol phosphate modification had gone unnoticed for decades due to loss during preparation steps," she said.
Because the Strep A bacteria is ranked among the top ten causes of mortality from infectious diseases in the world, the potential impact of a vaccine is considerable, particularly where resources and access to healthcare are limited.
"We need additional studies to demonstrate that this glycerol phosphate-modified glycopolymer can be included as a component of a safe and effective Group A Streptococcus vaccine" Korotkova said. "
Source: Eurekalert
Rheumatic Heart Disease (RHD)
Rheumatic heart disease is a sequelae of rheumatic fever that affects heart valves. Rheumatic fever occurs after an episode of strep throat or sore throat due to group A beta hemolytic streptococci.
Advertisement
The group of investigators -- led by Natalia Korotkova of the University of Kentucky and Nina Van Sorge of Utrecht University -- wondered: was there any "weak point" in the bacterial cell wall that could be exploited?
They found that both assays identified the same culprit: the gacH gene.
The team of more than a dozen scientists from five countries, each with a discrete expertise, further deciphered the function of this gene using a variety of biochemical, analytical and structural methods, determining that it enables Group A Streptococcus to reinforce its resistance to attack by our defense systems by modifying cell wall glycopolymers with glycerol phosphate.
"This previously unrecognized Streptococcus cell wall modification impacts host-pathogen interactions and might therefore be a very attractive target for vaccine design, especially since the gacH gene is widely distributed in the genomes of Group A Streptococcus and related bacteria," Korotkova said.
State-of-the-art NMR methods and mass-spectrometry analyses enabled the identification of this modification.
"This glycerol phosphate modification had gone unnoticed for decades due to loss during preparation steps," she said.
Because the Strep A bacteria is ranked among the top ten causes of mortality from infectious diseases in the world, the potential impact of a vaccine is considerable, particularly where resources and access to healthcare are limited.
"We need additional studies to demonstrate that this glycerol phosphate-modified glycopolymer can be included as a component of a safe and effective Group A Streptococcus vaccine" Korotkova said. "
Source: Eurekalert
Researchers Develop New Strep Throat Risk Score
A paper in the Annals of Internal Medicine says that a new risk measure called a home score could save a patient with symptoms of strep throat a trip to the doctor.
Advertisement
 Toxic Shock SyndromeToxic shock syndrome is a rare life-threatening medical condition caused by bacterial infections. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Brain plasticity following blindness leads to superior ability in sensing signals from the heart, which has implications for bodily awareness and emotional processing.
A group of scientists were awarded £1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.
Is there a connection between Osteoporosis and dementia? Yes, loss in bone density may be linked to an increased risk of dementia in older age.
Link between chromosome length and biological aging marker discovered. The finding helps explain why people with longer telomeres have a lower dementia risk.
Integrated structural biology helps discover how the cystic fibrosis transmembrane conductance regulator (CFTR) works.